A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/565 (2006.01) A61K 9/00 (2006.01) A61K 9/70 (2006.01) A61K 31/56 (2006.01) A61K 31/567 (2006.01) A61K 31/57 (2006.01) A61P 15/18 (2006.01)
Patent
CA 2478206
A method of contraception is described comprising the step of administering to a menstruating female a cycle of contraceptive therapy, said cycle of therapy including, for at most 35 successive days, the administration of a combination of an estrogen and a progestogen in a contraceptively effective daily dosage wherein said progestogen is a potent sulfatase inhibiting progestogen and said cycle of therapy including 4-8 days in which said progestogen is administered in the absence of estrogen administration following said at most 35 successive days.
L'invention porte sur une méthode contraceptive consistant à soumettre une femme réglée à un cycle de thérapie consistant à lui administrer pendant au plus 35 jours successifs une dose quotidienne à efficacité contraceptive d'une combinaison d'oestrogène, et d'un progestogène puissant inhibiteur de la sulfatase. Le cycle de thérapie comporte en outre une période de 4 à 8 jours faisant suite aux 35 jours où le progestogène est administré seul.
Caubel Patrick Michel
Friedman Andrew Joseph
Janssen Pharmaceutica N.v.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
LandOfFree
Sulfatase inhibiting continuous progestogen contraceptive... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfatase inhibiting continuous progestogen contraceptive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfatase inhibiting continuous progestogen contraceptive... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1505420